[Pilot study of SCH-12679 in profoundly mentally retarded patients with severe behavior disorders].
D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / Q000031:analogs & derivatives; D000328:Adult; D014151:Anti-Anxiety Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001552:Benzazepines / Q000009:adverse effects / Q000627:therapeutic use*; D002653:Child Behavior Disorders / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008607:Intellectual Disability / Q000150:complications*; D008297:Male
D014151:Anti-Anxiety Agents; D001552:Benzazepines; D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; C001016:trimopam
Etude pilote du SCH-12679 CHEZ DES ARRIERES MENTAUX PROFONDS PRESENTANT DES TROUBLES GRAVES DU COMPORTEMENT